Staar Surgical Co insider trading
Every open-market purchase and sale by Staar Surgical Co's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Staar Surgical Co’s insiders pay?
From September 10, 2010 to March 13, 2026, 33 insiders reported 63 open-market purchases and 116 sales not made under a pre-set plan in Staar Surgical Co. Twelve months after each purchase was reported, the shares were +9.6% against the S&P 500 on average (median −1.0%), over 58 purchases with a full year of prices; 50% beat the index. After sales, the shares moved +11.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 25, 2011 into $21,713 by November 2, 2026, +5.1% a year. It held shares 65% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $38,673 (+9.1% a year), and held throughout $74,251 (+13.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Broadwood Capital Inc | Director | 18 | −1.8% (16) | 38% | 6 | −48.3% (6) | March 13, 2026 |
| Bradsher Neal C | 10% owner | 20 | +3.7% (17) | 47% | 2 | −55.3% (2) | January 13, 2026 |
| Broadwood Partners, L.P. | 10% owner | 12 | +24.2% (12) | 75% | 2 | −50.4% (2) | April 7, 2025 |
| Andrews Deborah J | Chief Financial Officer | 0 | — | — | 13 | +23.8% (13) | March 24, 2020 |
| Holliday Keith | Chief Technology Officer | 0 | — | — | 13 | +40.0% (13) | March 17, 2023 |
| Francese James E | Sr. VP, Comm. Ops., NA, APAC | 0 | — | — | 12 | −2.6% (12) | September 29, 2022 |
| Gesten Samuel J | Chief Legal Officer | 0 | — | — | 9 | +37.7% (9) | October 5, 2021 |
| Blickensdoerfer Hans-Martin | Sr. VP, Comm. Ops, China | 0 | — | — | 8 | +47.6% (8) | September 9, 2021 |
| Hayashida Jon K. | VP, Global Clinical, Medical | 0 | — | — | 8 | +62.1% (8) | May 12, 2021 |
| Mason Caren L | President & CEO | 1 | 0.0% (1) | 100% | 6 | −0.8% (6) | May 20, 2022 |
| Hughes Robin | Vice President, R&D | 0 | — | — | 6 | −48.4% (6) | March 4, 2015 |
| Hansen Graydon C. | Sr. VP, Global Operations | 0 | — | — | 5 | +69.9% (5) | May 12, 2021 |
| Moore John C | Director | 2 | +94.3% (2) | 100% | 2 | +40.9% (2) | September 11, 2020 |
| Caldwell Barry G | President and CEO | 2 | +90.7% (2) | 100% | 1 | −39.2% (1) | November 14, 2012 |
| Goodmen William Walter | Global VP, Human Resources | 0 | — | — | 3 | −2.1% (3) | August 22, 2012 |
| Silverman Lou | Director | 1 | −2.0% (1) | 0% | 2 | −26.1% (2) | August 12, 2021 |
| Duffy Donald | Director | 0 | — | — | 2 | −47.4% (2) | November 2, 2011 |
| Fagen Donald L | V.P. Sales for N. America | 0 | — | — | 2 | −49.1% (2) | March 6, 2012 |
| Felberg Craig | VP, R&D and Clinical Affairs | 0 | — | — | 2 | −39.0% (2) | June 7, 2012 |
| Kaufman Charles S | V.P. , General Counsel | 0 | — | — | 2 | +2.3% (2) | August 26, 2011 |
| Morrison David R | Director | 0 | — | — | 2 | −52.5% (2) | December 2, 2011 |
| Todd Donald J | President, Asia/Pacific | 0 | — | — | 2 | −37.3% (2) | June 7, 2012 |
| Weisner Aimee S | Director | 2 | −48.8% (2) | 0% | 0 | — | March 14, 2024 |
| Williams Patrick F. | Chief Financial Officer | 0 | — | — | 2 | −27.0% (2) | September 17, 2021 |
| Bailey Don M | Director | 1 | −5.6% (1) | 0% | 0 | — | August 5, 2011 |
| Barnes Scott D | Chief Medical Officer | 0 | — | — | 1 | +117.4% (1) | November 15, 2019 |
| Butcher Arthur C | Director | 1 | −40.0% (1) | 0% | 0 | — | August 19, 2024 |
| Kamijo Isamu | President, STAAR Japan Inc. | 0 | — | — | 1 | +101.1% (1) | December 13, 2010 |
| Lin Elizabeth Yeu | Director | 1 | −58.2% (1) | 0% | 0 | — | September 22, 2023 |
| Logan Mark B | Director | 1 | +115.8% (1) | 100% | 0 | — | November 16, 2012 |
| Meier Richard A | Director | 0 | — | — | 1 | +62.5% (1) | May 23, 2016 |
| Wall William P | Director | 0 | — | — | 1 | −31.6% (1) | August 20, 2018 |
| Zhou Lilian Yansheng | Director | 1 | −49.8% (1) | 0% | 0 | — | December 6, 2023 |
When several insiders traded Staar Surgical Co
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Staar Surgical Co in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 8 buying crowds with six months of prices, it averaged −7.7% against the index. After 8 selling crowds, +25.7%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 2 buying | +35.6% | +3.0% | not yet |
| January 31, 2025 | 2 buying | −15.8% | −29.1% | −40.9% |
| September 29, 2023 | 4 buying | −34.0% | −23.8% | −45.5% |
| March 31, 2021 | 9 selling | +36.3% | +9.0% | −38.9% |
| September 30, 2020 | 3 selling | +28.5% | +66.5% | +97.3% |
| November 29, 2019 | 4 selling | −10.9% | +12.2% | +75.9% |
| March 29, 2019 | 4 selling | −18.3% | −29.6% | +4.7% |
| March 29, 2018 | 3 selling | +106.1% | +208.8% | +120.4% |
| January 29, 2016 | 2 buying | +11.0% | −8.5% | +28.6% |
| August 31, 2015 | 3 buying | −1.1% | −22.6% | −0.8% |
| November 28, 2014 | 2 buying | −18.2% | −3.9% | −11.7% |
| March 31, 2014 | 3 selling | −15.8% | −48.2% | −73.0% |